Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Receivables (2023 - 2025)

Krystal Biotech's Change in Receivables history spans 3 years, with the latest figure at -$2.5 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 133.45% year-over-year to -$2.5 million; the TTM value through Dec 2025 reached $22.1 million, down 64.72%, while the annual FY2025 figure was $22.1 million, 64.72% down from the prior year.
  • Change in Receivables for Q4 2025 was -$2.5 million at Krystal Biotech, down from $17.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $56.8 million in Q2 2024 and bottomed at -$5.9 million in Q3 2024.
  • The 3-year median for Change in Receivables is $7.8 million (2024), against an average of $12.7 million.
  • The largest annual shift saw Change in Receivables crashed 163.75% in 2024 before it soared 401.78% in 2025.
  • A 3-year view of Change in Receivables shows it stood at $32.7 million in 2023, then plummeted by 77.24% to $7.4 million in 2024, then crashed by 133.45% to -$2.5 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Change in Receivables are -$2.5 million (Q4 2025), $17.9 million (Q3 2025), and $8.2 million (Q2 2025).